|Day's Range||7.44 - 7.95|
|52 Week Range||2.35 - 8.72|
|PE Ratio (TTM)||-317.60|
|Earnings Date||Mar 31, 2017 - Apr 3, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||9.48|
The Phase II data for ibalizumab, a long-acting monoclonal antibody, show no significant difference in susceptibility (measured by maximum percent inhibition or ICHALFMAX Fold Change) in patient HIV isolates that were either sensitive or resistant to other antiretroviral agents, including nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, enfuvirtide and maraviroc. "HIV drug resistance is a key topic at the IAS conference this year, and these findings are particularly important as they suggest that ibalizumab is equally active against HIV whether it is resistant or responsive to approved antiretroviral agents," said Steve Weinheimer, Vice President, Biological Sciences at TaiMed Biologics USA.
NEW YORK, NY / ACCESSWIRE / July 20, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
This little-known marijuana company is the only real entry point into the multi-billion-dollar Canadian ...